Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9662629 | 0.93 | HMGCR (0.53) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL9662639 | 0.93 | HMGCR (0.53) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL9318838 | 0.91 | HMGCR (0.48) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL9320893 | 0.90 | HMGCR (0.41) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL9664038 | 0.84 | HMGCR (0.52) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL9664033 | 0.84 | HMGCR (0.52) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL9665217 | 0.83 | HMGCR (0.42) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL9665214 | 0.83 | HMGCR (0.42) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL10650833 | 0.82 | HMGCR (0.46) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL8953431 | 0.79 | HMGCR (0.61) | HMGCRESR1CHRM1TBXA2RPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0373423-B1 | Substituted 2-pyridones and pyride-2-thiones, process for their preparation and their use in medicine | BAYER AG (DE) | 1994-01-12 | — | — | EP | disclosed |